Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...

By Chris Wack Mustang Bio shares more than quadrupled, to $5.23, after the company on Monday said the Food and Drug Administration granted orphan drug designation to Mustang for MB-101 for the ...

The Internet Archive made it easier to search for '90s-era GIFs. GifCities contains millions of animations from the decade of flannel shirts and Soup Nazis. The GIFs were pulled from old GeoCities ...

The Internet Archive's vintage GIF search engine, GifCities, now supports keyword searches and searches by dimensions.

MEDIPAL HOLDINGS CORPORATION Public Relations Department TEL: (+81)-3-3517-5171 JCR Pharmaceuticals Co., Ltd. Corporate Communications TEL: (+81)-797-32-1995 ...

Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

Clinical-stage biotech firm Mustang Bio (NASDAQ:MBIO) stock rallied 180% on Monday to £2.46 ($3.34) per share after the US Food and Drug Administration granted Orphan Drug Designation to its MB ...

The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L) for treating steroid-refractory acute graft versus host disease (SR ...

The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

Peter Meeus, Commercial Excellence Executive, European Orphan Medicines Up until recently, Peter Meeus was the Head of Region Europe at Shire plc, the global leader in Rare Diseases, acquired by ...